Glucocorticoid Receptor 

 186 Products   186 Products   1696 Diseases   95004 News 


«12...178179180181182183184185186187188...10651066»
  • ||||||||||  budesonide / Generic mfg.
    Enrollment closed:  Acupuncture Therapy for COVID-Related Olfactory Loss (clinicaltrials.gov) -  Apr 7, 2023   
    P=N/A,  N=100, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
  • ||||||||||  Isturisa (osilodrostat) / Novartis, Recordati
    Ectopic ACTH syndrome secondary to metastatic liver cancer () -  Apr 6, 2023 - Abstract #AFMRSER2023AFMR_SER_81;    
    Following K supplementation, he was treated with furosemide, lisinopril, and spironolactone.Workup for an aldosteronism-type syndrome was sent including renin, aldosterone, cortisol (prior to MRA)...High dose dexamethasone (8 mg) had no effect in suppressing cortisol (203.9 mcg/dl), supporting ectopic ACTH secretion over pituitary ACTH hypersecretion...The cortisol synthesis inhibitor osilodrostat is being considered pending biopsy results.Overall, our patient had ectopic ACTH syndrome, likely of paraneoplastic origin, resulting in pseudohyperaldosteronism...Primary liver NET (if confirmed) would be very rare, accounting for only 0.3% of primary NET. To our knowledge, there are only 3 reported cases within the literature of a paraneoplastic ATCH syndrome secondary to hepatic NET.
  • ||||||||||  Kevzara (sarilumab) / Asahi Kasei, Regeneron, Sanofi
    Severe Covid-19 Infection Complicated by Hemophagocytic Lymphohistiocytosis (HLH) () -  Apr 6, 2023 - Abstract #AFMRSER2023AFMR_SER_18;    
    HLH can present with features indistinguishable from sepsis/septic shock or cytokine release syndrome and is increasingly recognized as a rare but serious complication of Covid-19 infection. Diagnosis is based on 9 criteria summarized by the HScore and early identification is critical in the management of this highly fatal disease with standard therapy of prolonged etoposide and dexamethasone.
  • ||||||||||  dexamethasone / Generic mfg., etoposide IV / Generic mfg.
    A Case of Hemophagocytic Lymphohistiocytosis Presenting as Acute Liver Failure () -  Apr 6, 2023 - Abstract #AFMRSER2023AFMR_SER_16;    
    Failed pharmacologic therapy may necessitate a hematopoietic stem cell transplantation. HLH requires a timely, multidisciplinary approach to ensure the best patient outcome.
  • ||||||||||  triamcinolone acetonide / Generic mfg.
    Trial completion date, Trial primary completion date, Head-to-Head:  Platelet-rich Plasma, Corticosteroid, or Lidocaine for Acromioclavicular Joint Pain (clinicaltrials.gov) -  Apr 6, 2023   
    P4,  N=150, Recruiting, 
    No abstract available Trial completion date: May 2024 --> Jul 2025 | Trial primary completion date: Dec 2023 --> Dec 2024
  • ||||||||||  budesonide / Generic mfg.
    Journal:  An update on corticosteroid treatment for IgA nephropathy. (Pubmed Central) -  Apr 5, 2023   
    Both reduced-dose corticosteroids and targeted-release budesonide are new therapeutic options that can be used in patients with high-risk disease. More novel-targeted therapies with a better safety profile are currently under investigations.
  • ||||||||||  Kenalog-40 (triamcinolone acetonide injection suspension) / BMS
    Journal:  Complications Following Facial Injection of Growth Factor Solution. (Pubmed Central) -  Apr 5, 2023   
    Although recurrence rate was relatively high, aesthetic, symptomatic, and psychological improvements were achieved in most patients. We developed a workflow that might help diagnose and treat complications following unknown dermal filler injections.
  • ||||||||||  Trial completion date, Trial primary completion date:  Immunotherapy for Neurological Post-Acute Sequelae of SARS-CoV-2 (clinicaltrials.gov) -  Apr 5, 2023   
    P2,  N=60, Enrolling by invitation, 
    Trial primary completion date: Dec 2022 --> Dec 2023 Trial completion date: Apr 2023 --> Apr 2024 | Trial primary completion date: Apr 2023 --> Apr 2024
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis
    Preclinical, Journal:  Preclinical Modeling of Intravitreal Suspensions. (Pubmed Central) -  Apr 4, 2023   
    By using such a model, a preclinical formulator may be able to more confidently determine if development of a complex formulation is required or if a simple suspension may work to support a study design. In this report, the model is used to predict the intravitreal preformance of two different molecules (triamcinolone acetonide and GNE-947) at multiple dose levels in rabbit eyes as well as provide a prediction for the performance of a marketed formulation of Trimacinolone Acetonide in humans.
  • ||||||||||  dexamethasone injection / Generic mfg.
    Preclinical, Journal:  Histological and Biomechanical Effects of Local Anesthetics and Steroids on Achilles Tendon: A Study in Rats. (Pubmed Central) -  Apr 4, 2023   
    Histological findings demonstrated that the group with the most toxicity to the tendon was the group that received injection of dexamethasone alone...In future clinical studies, the effect of steroids on the tendon should be investigated more comprehensively. Whether biomechanical results overlap with histological results should be investigated further.
  • ||||||||||  dexamethasone / Generic mfg.
    Review, Journal:  Possible, probable, and certain hypercortisolism: a continuum in the risk of comorbidity. (Pubmed Central) -  Apr 4, 2023   
    Mild hypercortisolism or autonomous cortisol secretion (ACS) is a term used for patients with adrenal incidentaloma and pathological dexamethasone suppression test (DST) results, but without specific clinical signs of hypercortisolism...In case of overt Cushing's syndrome, cardiovascular risk is extremely high, and standard mortality ratio is high, cardiovascular disease being the leading cause of death. The present review summarizes the current evidence for a detrimental cardiometabolic profile in patients with possible (NFAI), probable (ACS) and certain hypercortisolism (overt Cushing's syndrome).
  • ||||||||||  fluocinonide / Generic mfg.
    Trial completion date:  Cutaneous Lupus Medication Experience Study (clinicaltrials.gov) -  Apr 4, 2023   
    P=N/A,  N=11, Active, not recruiting, 
    Trial completion date: Aug 2023 --> Oct 2024 | Trial primary completion date: Aug 2023 --> Oct 2024 Trial completion date: Mar 2023 --> Jun 2023